CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Regenxbio Inc.  (RGNX)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
 

Regenxbio's Quick Ratio

RGNX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth



Select the Comparisons : Select the Ratio:                        

RGNX Quick Ratio (Sep 30 2017)
III. Quarter
(Jun 30 2017)
II. Quarter
(Mar 31 2017)
I. Quarter
(Dec 31 2016)
IV. Quarter
(Sep 30 2016)
III. Quarter
Y / Y Current Liabilities Change -51.75 % 90.17 % 259.67 % 35.23 % 1.28 %
Y / Y Cash & cash equivalent Change 81.61 % 72.05 % 44.29 % -21.54 % -56.99 %
Quick Ratio MRQ 64.25 41.05 35.31 58.04 17.07
Overall Ranking # 44 # 77 # 74 # 77 # 0
Seq. Current Liabilities Change -34.3 % -4.38 % 167.6 % -71.3 % 158.96 %
Seq. Cash & cash equivalent Change 2.83 % 11.16 % 62.82 % -2.41 % -2.59 %



Quick Ratio third quarter 2017 Comment
Regenxbio's Cash & cash equivalent grew by 2.83 % in III. Quarter sequntially, while Current Liabilities decreased, this led to improvement in Regenxbio's Quick Ratio to 64.25, Quick Ratio remained below Regenxbio Inc. average.

Within Biotechnology & Drugs industry Regenxbio Inc. achieved highest Quick Ratio than Regenxbio in third quarter 2017. While total ranking remained unchanged compare to previous quarter at no. .

Explain Quick Ratio?
What are RGNX Segments?
See Quick Ratio RGNX on the trailing twelve month basis
Quick Ratio third quarter 2017 Company Ranking
Within: No.
Biotechnology & Drugs Industry # 1
Healthcare Sector # 1
Overall Market # 44


Quick Ratio Statistics
High Average Low
100.04 54.37 17.07
(Dec 31 2015)   (Sep 30 2016)


You need to upgrade your Flash Player


Financial Statements
Regenxbio's Current Liabilities $ 3 Millions Visit RGNX's Balance sheet
Regenxbio's Cash & cash equivalent $ 167 Millions Visit RGNX's Balance sheet
Source of RGNX's Sales Visit RGNX's Sales by Geography




Companies with similar Quick Ratio in the quarter endingSep 30 2017, within Biotechnology & Drugs Industry Quick RatioSep 30 2017 MRQ Cash & cash equivalentSep 30 2017 MRQ Current Liabilities
Regenxbio Inc.  64.25 $ 166.662  Millions$ 2.594  Millions
Adverum Biotechnologies, Inc.  52.56 $ 186.642  Millions$ 3.551  Millions
Neuralstem, Inc.  39.28 $ 14.064  Millions$ 0.358  Millions
Microbot Medical Inc.  23.13 $ 11.729  Millions$ 0.507  Millions
Gtx Inc  21.88 $ 53.631  Millions$ 2.451  Millions
Acceleron Pharma Inc  21.30 $ 338.357  Millions$ 15.884  Millions
Crispr Therapeutics Ag  20.92 $ 253.519  Millions$ 12.117  Millions
Protokinetix, Inc.  19.48 $ 0.386  Millions$ 0.020  Millions
Artelo Biosciences, Inc.  19.48 $ 0.573  Millions$ 0.029  Millions
Pulse Biosciences, Inc.  16.99 $ 42.041  Millions$ 2.474  Millions
Spark Therapeutics, Inc.  15.46 $ 478.699  Millions$ 30.969  Millions
Aerie Pharmaceuticals Inc  15.13 $ 281.334  Millions$ 18.596  Millions
Neurocrine Biosciences Inc  13.40 $ 511.018  Millions$ 38.141  Millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

SFY's Profile

Stock Price

SFY's Financials

SFY's Expectations

Business Description

Fundamentals

Charts & Quotes

SFY's News

Suppliers

SFY's Competitors

Customers & Markets

Economic Indicators

SFY's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Expectations

Management Effectivness

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us



CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2017 CSIMarket, Inc. All rights reserved. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)
Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com